Liver impairment study for cancer drug tazemetostat halted early
NCT ID NCT04241835
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated early, so only limited information is available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tazemetostat (Tazverik)
What this could lead to
If successful, this could help doctors understand how to safely dose tazemetostat in cancer patients with liver problems.
What could go wrong
This was a very small, early-phase study that was terminated, so we may never get clear answers. It only looked at drug levels, not whether the drug works against cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital
Edegem, Antwerp, 2650, Belgium
-
Centre Oscar Lambret
Lille, 59020, France
-
Comprehensive Cancer Center of Nevada
Las Vegas, Nevada, 89014, United States
-
Florida Cancer Specialists & Research Institute
Lake Mary, Florida, 32746, United States
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
Hematology Oncology Consultants
Royal Oak, Michigan, 48073, United States
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut de Cancérologie Strasbourg Europe
Strasbourg, France
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
MedPolonia
Poznan, Greater Poland Voivodeship, 60693, Poland
-
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, 60611, United States
-
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
-
Summit Clinical Research, s.r.o
Bratislava, 831 01, Slovakia
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States